The Science of AllaQuix®: A Professional-Grade Hemostat

Abstract

AllaQuix® High Performance Stop Bleeding Gauze is a professional-grade hemostat designed for the management of minor cuts, abrasions, first-degree burns, and minor scalds. Composed of medical-grade chitosan, a biocompatible polysaccharide, AllaQuix® exhibits unique hemostatic, antimicrobial, and wound-healing properties. This article provides an in-depth review of the scientific foundation, mechanism of action, safety profile, and clinical applications of AllaQuix®. Emphasis is placed on its suitability for patients with clotting disorders, those on anticoagulant therapy, and other challenging cases.

 

Introduction

The effective management of minor wounds is crucial in medical settings, particularly for patients with compromised hemostatic function. AllaQuix® High Performance Stop Bleeding Gauze is a sterile, topical wound dressing cleared by the FDA for over-the-counter (OTC) use. By leveraging the properties of chitosan, AllaQuix® provides a rapid and reliable solution for stopping minor bleeding. This article explores its history, scientific basis, and practical use in clinical environments.

 

The Science of Chitosan

History and Development

Chitosan has been investigated as a hemostatic agent since the 1980s, with early studies conducted by Malette and Quigley. Over the past four decades, numerous studies have demonstrated the efficacy and safety of chitosan-based products, leading to their adoption in surgical, trauma, and military applications. Today, AllaQuix® brings these benefits to medical professionals and consumers alike for the management of minor bleeding.

"A professional-grade tool trusted by the U.S. military, now available for managing minor wounds in everyday clinical practice."

 

Mechanism of Action

Chitosan’s hemostatic properties arise from its ionic interaction with red blood cell membranes. The positively charged chitosan fibers attract negatively charged red blood cells, forming a stable coagulum independent of the clotting cascade. This mechanism allows AllaQuix® to be effective even in patients with clotting disorders or those on anticoagulant therapy.

"Chitosan’s unique ionic interaction with red blood cells ensures rapid and stable clot formation."


Clinical Applications

Indications for Use

AllaQuix® is FDA-cleared for the management of minor topical wounds, including:
  • Minor cuts and abrasions
  • First-degree burns
  • Minor scalds
  • Lacerations

Special Populations

The unique properties of AllaQuix® make it particularly valuable for patients:

  • On anticoagulant therapy (e.g., Warfarin, Eliquis, Pradaxa)
  • With bleeding or clotting disorders (e.g., hemophilia, von Willebrand disease)
  • With thin or fragile skin

"AllaQuix® works independently of the clotting cascade, making it ideal for patients on anticoagulants."

 

Safety Profile

General Safety

AllaQuix® has an excellent safety profile with no reported contraindications or age restrictions. Each pad is sterilized through gamma irradiation, ensuring a high level of safety for clinical use.

Shellfish Allergy Considerations

Chitosan is derived from shellfish; however, the manufacturing process effectively removes allergenic proteins. A study published in Military Medicine demonstrated that patients with known shellfish allergies tolerated chitosan bandages without adverse reactions. Nonetheless, individuals with shellfish allergies should use AllaQuix® with caution.

Usage Precautions

  • Not for medical emergencies or serious wounds
  • Not a replacement for stitches
  • Avoid use on visibly infected wounds
  • Prolonged compression may be necessary for hypertensive or overweight patients

 

    Discussion

    Advantages of AllaQuix®

    AllaQuix® offers several advantages over traditional wound care products, including:

    • Rapid and effective control of bleeding
    • Independence from the body’s clotting cascade
    • Ease of use and removal
    • No irritation, burning, or stinging
    • Flexible and adaptable to various wound sizes

    "AllaQuix® is easy-on, easy-off, with no preparation or special storage required."

    Economic Value

    With a cost of just a few dollars per application, AllaQuix® provides an economical solution for medical professionals seeking a reliable hemostatic agent. Compared to other professional-grade hemostats, it is a cost-effective choice without compromising efficacy.
     

    "Less than $10 per application: an economical solution without compromising quality."

     

    Conclusion

    AllaQuix® High Performance Stop Bleeding Gauze is a game-changing hemostatic solution for the management of minor bleeding. Its proven efficacy, safety, and ease of use make it a valuable tool for medical professionals, including dermatologists, surgeons, school nurses, athletic trainers, and first responders. With its foundation in decades of chitosan research, AllaQuix® stands as a professional-grade product now accessible to a wider audience.


     

     

    CAUTION

    For medical emergencies, serious wounds, or if bleeding persists, seek immediate professional medical help.  Does not replace stitches – seek medical attention if stitches needed.  Do not use on visibly infected wounds – seek medical attention.

    Read full Instructions for Use before using any Inspiration Medical Technology product.
     

    Scientific References

    Acheson EM, Kheirabadi BS, Deguzman R, Dick EJ Jr, Holcomb JB. Comparison of hemorrhagic control agents applied to lethal extremity arterial hemorrhage in swine. J Trauma. 2005; 59:865-75.

    Alam HB, Uy GB, Miller D, et al. Comparative analysis of hemostatic agents in a swine model of lethal groin injury. J Trauma. 2003; 54:1077–82.

    Alam HB, Burris D, DaCorta JA, Rhee P. Hemorrhage control in the battlefield: role of new hemostatic agents. Mil Med. 2005; 170(1):63–9.

    Balassa LL, Prudden JF. Applications of chitin and chitosan in wound-healing acceleration. In: Murrarelli RAA, Pariser ER (eds) Proceedings of the First International Conference on Chitin/Chitosan. Boston. 1978. 296–305 .

    Brandenberg G, Leibrock LG, Shuman R, Malette WG, Quigley H. Chitosan: a new topical hemostatic agent for diffuse capillary bleeding in brain tissue. Neurosurgery. 1984;15:9–13.

    Chan MW, Schwaitzberg SD, Demcheva M, Vournakis J, Finkielsztein S, Connolly RJ. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. J Trauma. 2000;48:454–458.

    Chou, Tz-Chong, Earl Fu, Chang-Jer Wu, Jeng-Hsien Yeh. Chitosan enhances platelet adhesion and aggregation. Biochemical and Biophysical Research Communications. 2003; 302(3): 480–83.

    Cole DJ, Connolly RJ, Chan MW, et al. A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent. J Surg. 1999;126:510–517.

    Evans EE, Kent SP. The use of basic polysaccharides in histochemistry and cytochemistry: IV—precipitation and agglutination of biological materials by aspergillus polysaccharide and deacetylated chitin. J Histochem Cytochem. 1962; 10:24–28.

    Fradet G, Brister S, Mulder DS, Lough J, Averbach BL. Evaluation of chitosan as a new hemostatic agent: In vitro and in vivo expression. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York. 1986; 443–451.

    Fukasawa M, Abe H, Masaoka T, et al. The hemostatic effect of deacylated chitin membrane on peritoneal injury in a rabbit model. Surg Today. 1992;22:333–338.

    Janvikul, W, Uppanan, P, Thavornyutikarn, B, Krewraing, J. and Prateepasen, R. In vitrocomparative hemostatic studies of chitin, chitosan, and their derivatives. J. Appl. Polym. Sci., 1986; 102: 445–451.

    Jewelewicz DD, Cohn SM, Crookes BA, Proctor KG. Modified rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury. J Trauma. 2003; 55:275–81.

    Kind GM, Bines SD, Staren ED, Templeton AJ, Economou SG. Chitosan: evaluation of a new hemostatic agent. Curr Surg. 1990; 47:37–39.

    Klollevold PR, Lew DS, Ellis DG, Bertolami CN. Effect of chitosan on lingual hemostasis in rabbits. J Oral Maxillofac Surg. 1991; 49:858–863.

    Klokkevold PR, Subar P, Fukayama H, Bertolami CN. Effect of chitosan on lingual hemostasis in rabbits with platelet dysfunction induced by epoprostenol. J Oral Maxillofac Surg. 1992;50:41–45.

    Klokkevold PR, Fukayama H, Sung EC, Bertolami CN. The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. J Oral Maxillofac Surg. 1999;57:49–52.

    Komlos L, Ben-Efraim S, Lewis NJ, Hart J, Halbrecht I. Synergistic effect of N-acetyl-D-glucosamine (NAG) on mitogenic, antigenic and allogenic stimulation of normal lymphocytes. Int J Immunopharmacol. 1984;6:593–599.

    Lord, MS, Cheng, B, McCarthy, SJ, Jung, MS, Whitelock, JM. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins, Biomaterials. 2001: 32(28): 6655-62.

    Lord, MS, Yu, W, Cheng, B, Simmons, A, Poole-warren, L, Whitelock, JM.  The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. Biomaterials. 2009; 30(28): 4898–4906.

    Malette WG, Quigley HJ, Gaines RD, Johnson ND, Rainer WG. Chitosan: A new hemostatic. Ann Thorac Surg. 1983; 36:55–58.

    Malette WG, Quigley HJ Jr, Adickes ED. Chitosan effect in vascular surgery, tissue culture and tissue regeneration. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York,. 1986; 435–442.

    Minami S, Suzuki H, Okamato Y, Fujinaga T, Shigemasa Y. Chitin and chitosan activate complement via alternative pathway. Carbohydr Polym. 1998;36:151–155.

    Mori T, Okumura M, Matsura M, et al. Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials. 1997;18:947–51.

    Muzzarelli RA, Mattioli-Belmonte M, Pugnaloni A, Biagini G. Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. In: Jolles P, Muzzarelli RA, eds. Chitin and Chitinases. Basel, Switzerland: Birkhauser Verlag; 1999:251–264.

    Nishimura K, Nishimura S, Nishi N, Tokura S, Azuma I. Immunological activity of chitin derivatives. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York. 1986; 477–83.

    Okamoto, Y, Yano, R, Miyatake, K, Tomohiro, I, Shigemasa, Y. Minami, S. Effects of chitin and chitosan on blood coagulation. Carbohydrate Polymers. 2003; 53(3): 337-42

    Peh KK, Khan TA, Ch’ng HS. Mechanical, bioadhesive strength and biological evaluation of chitosan films for wound dressing. J Pharm Pharm Sci. 2000;3:303–311.

    Pruden JF, Migel P, Hanson P, Friedrich L, Balassa L. The discovery of a potent pure chemical wound-healing accelerator. Am J Surg. 1970;119:560–64.

    Pusateri AE, Holcomb JB, Kheirabadi BS, Alam H, Wade CE, Ryan KL. Making sense of the preclinical literature on advanced hemostatic dressings. J Trauma. 2006; 60(3):674–82.

    Pusateri AE, McCarthy SJ, Gregory KW, et al. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. J Trauma. 2003a; 54:177–82.

    Rao, S. B. and Sharma, C. P. Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 1997; 34: 21–28.

    Schmidt RJ, Chung LY, Andrews AM, Spyratou O, Turner TD. Biocompatibility of wound management products: a study of the effects of various polysaccharides on murine L929 fibroblast proliferation and macrophage respiratory burst. J Pharm Pharmacol.1993;45:508–513.

    Sugamori, T., Iwase, H., Maeda, M., Inoue, Y. and Kurosawa, H. Local hemostatic effects of microcrystalline partially deacetylated chitin hydrochloride. J. Biomed. Mater. Res. 2000; 49: 225–232.

    Suzuki K, Tokoro A, Okawa Y, Suzuki S, Suzuki M. Effect of Nacetylchito-oligiosaccharides on activation of phagocytes. Microbiol Immunol. 1986;30:777–787.

    Tanigawa T, Yoshinori T, Tomita K, et al. Effect of chitin on the production of interleukin-1b in human blood monocytes. Yonago Acta Med. 1992;35:147–150.

    Tokura S, Tamura H, Azuma I. Immunological aspects of chitin and chitin derivatives administered to animals. In: Jolles P, Muzzarelli RA, eds. Chitin and Chitinases. Basel, Switzerland: Birkhauser Verlag; 1999:279–292.

    Wedmore I, McManus JG, Pusateri AE, Holcomb JB. The chitosan-based hemostatic dressing: Experience in current combat operations. J Trauma. 2006; 60(3):655–8.

    Yang, J., Tian, F., Wang, Z., Wang, Q., Zeng, Y.-J. and Chen, S.-Q. (2008), Effect of chitosan molecular weight and deacetylation degree on hemostasis. J. Biomed. Mater. Res., 84B: 131–137.